COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors

Protocol No
INHIBRX-PH1-INBRX-106
Principal Investigator
Jonathan Thompson
Phase
I
Summary
To assess the safety, tolerability, and dose-limiting toxicities (DLTs) of INBRX-106 as a single agent administered as an IV infusion at escalating dose levels in adult subjects with locally advanced or metastatic solid tumors. To assess the safety, tolerability, and DLTs of INBRX-106 in combination with pembrolizumab administered as an IV infusion at escalating dose levels in adult subjects with locally advanced or metastatic solid tumors. To determine the maximum tolderated dose and/or the recommended Phase 2 dose of INBRX-106 as a single agent when adminisered as an IV infusion and in combination with pembrolizumab.
Description
To assess the safety, tolerability, dose-limiting toxicities (DLTs), and determine the maximum tolerated dose of INBRX-106 as a single agent administered as an intravenous infusion and in combination with pembrolizumab.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL